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Summary.-A new series of LH-RH analogues containing an Azgly'O modification
and having potent agonist properties were given in high concentration to intact
female rats. Plasma LH and FSH were raised to extremely high levels after 14 days'
administration of the compounds (5.0 and 0-5 /Lg/rat twice daily), but plasma
oestradiol concentrations were reduced to those in ovariectomized rats. The weights
ofthe ovary and uterus were also markedlyreduced, suggestingthatthesecompounds
are, on this treatment regime, producing the effects of chemical castration.
FOLLOWING the elucidationi ofthe struc-
ture of luteinizing hormone-releasing hor-
mone (LH-RH) (Matsuo et al., 1971;
Baba et al., 1971) many synthetic ana-
logues have been prepared with enhanced
activity. Recently a new series of LH-RH
analogues containing an azaglycine residue
in Position 10 has been synthesized
(Dutta et al., 1978a). One of these com-
pounds, [D-Ser(But)6, Azglyl°]LH-RH
(ICI 118630) induced ovulation in andro-
gen-sterilized constant-oestrus rats after
i.v. injection of doses as low as 5 ng/rat.
When given at higher doses (0.5 to 5 0 ug/
rat) it inhibited HCG-stimulated uterine
growth in rats (Dutta et al., 1978a).
These properties are similar to those of
another LH-RH analogue, [D-LeU6,
des-GlyNH210 Proethylamide9]LH-RH
(A43818) (Rippel et al., 1975; Rippel &
Johnson, 1976).
A more extensive study of the effects of
high doses of ICI 118630 and of 3 other
LH-RH agonist analogues on the plasma
levels of several hormones in rats was
undertaken, together with an examination
of the effects on some endocrine target
organs. This work was performed in con-
junction with an evaluation of the effec-
tiveness of such LH-RH analogues in
causing regression of dimethylbenz(a)-
anthracene (DMBA)-induced mammary
tumours in the rat, the results of which
are reported in the accompanying paper
(Nicholson & Maynard, 1978).
MATERIALS AND METHODS
Peptides.-The 4 peptides (Table I) used
in these studies were synthesized by solution
methods (Dutta et al., 1978b) by Dr A. S.
Dutta, ICI Pharmaceuticals Division, Mac-
clesfield, England. The purity of each peptide
wvas >95%o, as assessed by thin-layer
chromatography, paper electrophoresis and
amino-acid analysis.
Animnals. Mature virgin female Sprague-
Dawley rats bred in the Institute were used
throughout the study. The animals were
housed in a 12 h light/12 h dark environment
and had access to feed and wN-ater ad lib.
The peptides were dissolved in physio-
logical saline and administered as an i.m.
injection (100 [L) into the rear legs of the
rats, betwAeen 09.00 and 10.00 and also, when
twice-daily injections wvere made, between
15.30 and 16.30.
When animals were to be killed, blood
samples were obtained after decapitation
or via the dorsal aorta under ether anaes-
thesia. If recovery of the rat was desired,
small samples of blood (up to 2 ml) were
taken from one of the jugular veins.EFFECTS OF LH-RH ANALOGUES IN FEMALE RATS
TABLE I.-LH-RH analogues used in the study
ICI 118630 [D-Ser(But)6,AzG1310]LH-RH
ICI 115605 [D-Phe6,AzGlylO]LH-RH
ICI 123220 [D-Tyr (0-Me)6,AzGly'O]LH-RH
ICI 123215 [D-Ser(But)6,desG1y-NHI21O, Proethylamide9]LH-RH
Organ weights were expressed as a fraction
of the total body weight of the animal at the
start of the experiment.
Plasma hormone assays.-Oestradiol was
measured in non-chromatographed ether
extracts ofthe plasmas, using aradioimmuno-
assay technique. The antiserum was raised
in rabbits against oestradiol linked to bovine
serum albumin through the 6 position. The
assay had a cross-reaction of less than 1%
with other common oestrogens and C09-
steroids, and had a sensitivity of 1-7 pg.
The protein hormones LH and FSH were
measured byadouble-antibodyradioimmuno-
assay procedure similar to that described by
Groom (1977) for human pituitary hormones,
but using materials contained in kits obtained
from NIH.
RESULTS
The temporal effects on plasma LH
levels of a single injection of 5.0 ,ug of
one compound, ICI 118630, were examined
(Fig. 1). There was a rapid increase in
immunologicallyreactive LHintheplasma
which reached peak concentration at
1-2 h after administration of the LH-RH
analogue. Plasma concentration of LH
had fallen considerably, but not to basal
values, 6-8 h after the injection.
Since the biological effects of similar
compounds were usually most noticeable
after twice-daily administration, the
plasma LH profile was obtained on this
regime (Fig. 2). The second injection
(also of 5-0 pg) given 7 h after the first,
again caused a peak of LH in the plasma
after about 1-2 h, though the second peak
was not as high as the first. By the follow-
ing morning plasma LH concentration was
indistinguishable from control.
A similar pattern of plasma LH release
was found after 14 days of twice-daily
injection of 5 0 Hg ICI 118630 (Fig. 3),
although the levels ofLH andthe quantity
released were considerably lower than on
the first day of treatment.
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FIG. 1.-Plasma LH levels in rats given one
i.m. injection of 5-0 jug ICI 118630 (0-0)
or saline (0-0) at Time 0. Points indica-
ted are the mean of 5 animals ±s.e.
The effect on intact female animals of
2 dose levels of each analogue was
examined after 14 days of treatment, the
doses being 5-0 pg and 0-5 ,g per injection
given twice daily. Table II shows the
plasma hormone concentrations in the
various groups; blood was taken after
decapitation without anaesthesia 1 h after
the final injection.
Alltreatmentgroupsandovariectomized
animals showed a significant (P<0-5,
Mann-Whitney U test) elevation of LH
levels over controls, and many of the
animals receiving LH-RH analogues had
higher LH concentrations than ovari-
ectomized rats.
The synthetic analogues also raised
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FIG. 2.-Plasma LH levels in rats given one i.m. injection of 5 0,ug ICI 118630 at 09.00 and one at 16.00 h.
Values are the mean±s.e. for 5 animals.
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FIG. 3.-Plasma LH levels in rats treated for 14 days previouslv with twice-daily injection of 5-0 jug ICI
118630. Injections on day of sampling at 09.00 and 16.00 h. Values are meanis.e. for 5 animals.
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TABLE II.-Plasma hormone levels in rats 1 h after thefinal morning injection of LH-RH
agonist analogues, comnpared with saline-treated control and ovariectomized animals.
The animals were given twice-daily injections of the compound, either 05 ltg or 5 0 ,ug
per injection for 14 days before blood samnpling. Also shown are results using 0-05 1tg
ICI 118630 per injection. Blood was collected after decapitation of the animals without
anaesthesia. Levels expressed as means with the range of values in parentheses.
Group
Control
ICI 118630 (0 5 ,ug)
ICI 118630 (5.0 jig)
ICI 118630 (0 05 ,ug)
ICI 115605 (0 5 jig)
ICI 115605 (5.0 ,ug)
ICI 123220 (0 5 ,ug)
ICI 123220 (5 0 ,ig)
ICI 123215 (0 5 jig)
ICI 123215 (5 0 ,ug)
Ovariectomy
No. animals
per group LH (ng/ml)
6 48
(20-145)
6 tt527**
(412-763)
6 tt522**
(443-805)
8 tt778**
(431-1242)
6 t473**
(346-626)
6 465**
(309-780)
6 t445*
(329-520)
6 366*
(283-540)
6 tt648**
(477-920)
6 tt578**
(413-665)
7 315**
(119-444)
* Significantly different from control
**
t ,, ,, ,. ovariect
It ,. .. .. .
(P<0*05)
(P<0 005)
tomy (P<0 05)
(P<0-005)
FSH (ng/ml)
905
(583-1211)
t1764*
(1421-2255)
2631**
(2229-2913)
tl857**
(1507-2324)
t1735*
(1293-2197)
tl802*
(1630-2049)
ttl662**
(1306-2002)
tl967**
(1095-2823)
tl892**
(1242-2934)
3202**
(1931-3727)
Mann-Whitney
U Test
Oestradiol (pg/ml)
32-8
(11 1-645)
8-5**
(6-1-12-2)
8-2**
(3-2-14-3)
12-3*
(10-8-16-8)
8-0**
(5.2-89)
12-1*
(7-1-18-6)
tl5.3
(12-7-20-1)
9-5**
(6-1-17-3)
17-0
(11-9-26-2)
10.5*
(5-2-14-8)
8-7*
(3.5-26.0)
plasma FSH levels significantly above
control values, but not to the levels
attained in the ovariectomized group.
It is also clear from Table II that
administration of either dose level of the
LH-RH analogues reduced circulating
oestradiol concentrations to those in
ovariectomized rats. Vaginal smears taken
at necropsy showed many more of the
treated ratsthan controlswere in dioestrus.
Table III shows the effects of the LH-
RH analogues on the weight of several
organs in the animals compared with
thoseofcontrolandovariectomizedgroups.
All the compounds caused a slightly
higher total weight gain than the controls,
which was comparable to that produced
by ovariectomy. Kidney weights were
always similar to the control animals, but
adrenal and pituitary weights were re-
duced, again to an extent similar to that
in ovariectomized animals. All the syn-
thetic LH-RH analogues caused a small
decrease in ovarian weight, particularly
at the higher dose levels, but the most
marked effect was on the uterus. Com-
pounds ICI 118630 and ICI 115605 both
caused a decrease in uterine weight to
values indistinguishable from those of
ovariectomized animals. Compounds ICI
123220 and ICI 123215 caused a decrease
in uterine weight but, particularly at the
lower dose level, not as dramatically as
ovariectomy.
Because 0 5 [kg ICI 118630 reduces
plasma oestradiol and uterine weight, a
lower dose level was evaluated: 0-05 [kg
twice daily. A further group ofanimals was
treated in an identical manner and the
results are given in Tables II and III.
The LH levels were similar to those in
animals given higher doses, but there was
not such a dramatic decrease in plasma
oestradiol or in uterine weight. No dif-
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ferences in pituitary or ovarian weights
were found.
DISCUSSION
The effect of LH-RH agonists of
inhibiting HCG-induced uterine growth
when administered at high doses (Rippel
& Johnson, 1976; Dutta et al., 1978a)
prompted a more detailed investigation
into the biological results of such treat-
ment with LH-RH agonists containing
the AzglylO modification. From studies
of the time course of plasma LH levels
after injection of ICI 118630 (Figs. 1-3)
it is clear that it is indeed an extremely
potent LH-RH agonist. Even after 14
days of continuous administration, it
elicits amarkedandextendedrelease ofLH.
Nevertheless, all these analogues do
reduce plasma oestradiol levels consider-
ably (Table II), and the effects on organ
weights (Table III) are consistent with
this finding. In this respect, ICI 118630,
with an AzglylO residue, is more effective
at causing a decrease in uterine weight in
intact female rats than a similar com-
pound with a Proethylamide9 C-terminal
grouping (ICI 123215) (see Table III).
It is apparent that this effect is dose
dependent, since the twice-daily adminis-
tration of 0 05 tg of ICI 118630 did not
cause as great a decrease in uterine weight
as higher dose levels, nor were oestradiol
concentrations reduced so markedly, des-
pite levels of LH being equally high 1 h
after injection.
The mechanism whereby injection of
LH-RH analogues can greatly elevate
plasma LH levels and yet cause a reduc-
tion in plasma oestradiol (Table II) is
not fully understood. There are, however,
a number of theoretical explanations for
this phenomenon. Firstly, it is possible
that the LH-RH analogue may have a
direct effect on the ovary, rendering it
incapable of responding, by increased
steroidogenesis, to LH stimulation. Sec-
ondly, the production of extremely high
levels of circulating LH may block the
physiological action of LH at the ovary
and inhibit synthesis of the LH receptor
(Zor et al., 1972). Thirdly, it is possible
that continued overstimulation of the
pituitary may cause the production of
immunologically reactive LH with no
biological activity.
These effects could have a practical
application in certain clinical situations.
For example, hormone-dependent meta-
static breast cancer in premenopausal
women may possibly be treated by such a
chemical oophorectomy. Moreover, women
who are most likely to respond to surgical
castration might be selected after a short
course of treatment with an LH-RH
agonist.
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